Revive Seeks To Advance Bucillamine Study To Phase 2 Clinical Study
This morning, Revive Therapeutics (CSE: RVV) released an update in relation to its ongoing study of Bucillamine for the use
Read more
Revive Therapeutics
Revive Selects Pharm-Olam As Contract Research Organization For Infectious Disease Study
This evening, Revive Therapeutics (CSE: RVV) announced that the company has signed with a contract research organization to advance its
Read more
Revive Appoints Infectious Disease Expert As Scientific Adviser
Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as scientific advisor, aimed at assisting
Read more
Revive Explores Use of Bucillamine For Infectious Disease
Revive Therapeutics (CSE: RVV) announced this morning that it has applied for a provisional patent related to that of the
Read more
Revive Closes Psilocin Pharma Acquisition, Releases Psilocybin Patent Details
Revive Therapeutics (CSE: RVV) has completed its previously announced acquisition of Psilocin Pharma Corp, a specialty psychedelic pharma corporation that
Read more
Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?
Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded. Presumably, RVV is beginning to
Read more